2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P07. Management of Advanced Non-small Cell Lung Cancer Patients Harbouring ROS1 Rearrangement- Experience From a Tertiary Cancer Centre in Eastern India

P07. Management of Advanced Non-small Cell Lung Cancer Patients Harbouring ROS1 Rearrangement- Experience From a Tertiary Cancer Centre in Eastern India - PDF

Back to course

Pdf Summary

This abstract discusses the management of advanced non-small cell lung cancer (NSCLC) patients with ROS1 gene rearrangement in a tertiary cancer center in Eastern India. The study aimed to evaluate the outcomes of these patients and audit the institutional practice.<br /><br />The study included 29 NSCLC patients with ROS1 mutation out of 1,019 screened from 2017 to 2020. Among these patients, two were treated with a radical intent, one progressed and received palliative therapy, and the remaining 26 were treated with palliative intent. Of the 26 patients, 20 received systemic therapy, while the remaining eight were in poor performance status and could not receive any form of anticancer therapy.<br /><br />The median age of the patients was 54 years, and 13 of them were female. Two patients had brain metastasis at presentation. Twelve patients received first-line treatment with tyrosine kinase inhibitors (TKIs) such as Crizotinib and Ceritinib, while eight patients received platinum-based doublet chemotherapy. The median progression-free survival was 13 months for those on chemotherapy and 10 months for those on TKIs. The overall survival was not significantly different between the two groups.<br /><br />The study concluded that access to targeted therapies remains limited in developing countries, leading to some patients receiving first-line chemotherapy due to financial constraints. However, the outcomes of chemotherapy were comparable to TKIs, suggesting that chemotherapy can be a feasible option for advanced NSCLC patients with ROS1 mutation.<br /><br />Overall, this study highlights the challenges in providing targeted therapies for lung cancer in developing countries and suggests that chemotherapy can be an effective alternative in certain cases.

Asset Subtitle

Saheli Saha

Meta Tag

Speaker Saheli Saha

Topic Targeted Therapies - ALK & ROS1 Inhibitors

Keywords

advanced non-small cell lung cancer

NSCLC

ROS1 gene rearrangement

tertiary cancer center

Eastern India

outcomes

institutional practice

systemic therapy

tyrosine kinase inhibitors

chemotherapy